ARLINGTON, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative ...

Kala Bio focuses on developing therapies for rare and severe diseases of the eye using its proprietary mesenchymal stem cell secretome platform. Its lead product candidate, KPI-012, had previously ...

The latest price target for Kala Bio (NASDAQ:KALA) was reported by HC Wainwright & Co. on September 29, 2025. The analyst firm set a price target for $0.00 expecting KALA to fall to within 12 months ...

Jacob Durso is a therapist with Optimum Care Counselling. He graduated with an MSW from Slippery Rock University. Jacob is also certified in cognitive behavioral therapy(CBT), which aims to help ...

Investment to support the continued evaluation and redevelopment of KALA’s product candidates and patent portfolio, and provide working capital and funding for a potential future strategic transaction ...

This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed.

KALA BIO Inc. Kala Bio, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based mucus penetrating particles with ...

Districts in poorer areas are the hardest hit by the budget impasse, as they tend ...

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.